Follow the Helix BioPharma Corp. stock price and the full management transaction log of the company, a listed equity based in Canada. Shares are listed on the CA market, under the supervision of SEDI. Operating in the Health Care sector, Helix BioPharma Corp. has published 11 insider filings. Market capitalisation: €142.8m. The latest transaction was reported on 10 August 2026 (55 - Expiration of warrants). Among the most active insiders: Wilczewski, Jerzy. Every trade is openly available.
11
Insider Decl.
n/a
Thresholds
n/a
n/a
Buy Volume
n/a
n/a
Sell Volume
Σ
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.